Literature DB >> 1516286

Serum and urinary ceruloplasmin in experimental nephrotic syndrome.

A Mainero1, C Cruz, J Pedraza-Chaverrí.   

Abstract

The levels of ceruloplasmin (Cp) and total protein were measured in serum and urine from rats with experimental nephrotic syndrome (NS) for 20 days after a single injection of puromycin aminonucleoside (PAN). Control values for Cp in serum and urine were: 0.23 +/- 0.01 mg/ml and 0.063 mg/day, and those for total protein were: 7.1 +/- 0.14 g/dl and 2.1 +/- 0.6 mg/day, respectively. It was found that: a) serum Cp decreased on day 6, remained low until day 10 (0.07 +/- 0.01 to 0.08 +/- 0.01 mg/ml), and returned to control levels on day 12; b) total serum protein decreased on day 4, reached the lowest value on day 6 (3.3 +/- 0.3 g/dl) and returned to control levels on day 16; c) Cp in urine increased on day 6, reached a peak value on day 8 (0.62 +/- 0.07 mg/day), then decreased but remained high on day 20; and d) total protein in urine increased on day 5, reached a peak value on day 10 (692 +/- 59 mg/day) and returned to control values on day 20. There was a close association between the levels of Cp and total protein in serum and urine. The decrease of circulating Cp indicates that a typical acute phase response does not occur in the PAN-nephrotic rats. The loss of Cp in the urine of the nephrotic rats may contribute to the decrease in the serum levels of this protein.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1516286

Source DB:  PubMed          Journal:  Clin Invest Med        ISSN: 0147-958X            Impact factor:   0.825


  2 in total

1.  The optimal threshold of serum ceruloplasmin in the diagnosis of Wilson's disease: A large hospital-based study.

Authors:  Rong Xu; Yong-Fang Jiang; Yong-Hong Zhang; Xu Yang
Journal:  PLoS One       Date:  2018-01-11       Impact factor: 3.240

2.  Non-Wilson's Disease-Associated Hypoceruloplasminemia.

Authors:  Annie Gong; Samantha Leitold; Julia Uhanova; Gerald Y Minuk
Journal:  J Clin Exp Hepatol       Date:  2019-11-26
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.